1125 related articles for article (PubMed ID: 24675665)
1. Hepatic overexpression of idol increases circulating protein convertase subtilisin/kexin type 9 in mice and hamsters via dual mechanisms: sterol regulatory element-binding protein 2 and low-density lipoprotein receptor-dependent pathways.
Sasaki M; Terao Y; Ayaori M; Uto-Kondo H; Iizuka M; Yogo M; Hagisawa K; Takiguchi S; Yakushiji E; Nakaya K; Ogura M; Komatsu T; Ikewaki K
Arterioscler Thromb Vasc Biol; 2014 Jun; 34(6):1171-8. PubMed ID: 24675665
[TBL] [Abstract][Full Text] [Related]
2. Effect of Porphyromonas gingivalis infection on post-transcriptional regulation of the low-density lipoprotein receptor in mice.
Miyazawa H; Tabeta K; Miyauchi S; Aoki-Nonaka Y; Domon H; Honda T; Nakajima T; Yamazaki K
Lipids Health Dis; 2012 Sep; 11():121. PubMed ID: 22992388
[TBL] [Abstract][Full Text] [Related]
3. Suppression of Idol expression is an additional mechanism underlying statin-induced up-regulation of hepatic LDL receptor expression.
Dong B; Wu M; Cao A; Li H; Liu J
Int J Mol Med; 2011 Jan; 27(1):103-10. PubMed ID: 21069265
[TBL] [Abstract][Full Text] [Related]
4. Role of PCSK9 and IDOL in the pathogenesis of acquired LDL receptor deficiency and hypercholesterolemia in nephrotic syndrome.
Liu S; Vaziri ND
Nephrol Dial Transplant; 2014 Mar; 29(3):538-43. PubMed ID: 24166456
[TBL] [Abstract][Full Text] [Related]
5. Reduced VLDL clearance in Apoe(-/-)Npc1(-/-) mice is associated with increased Pcsk9 and Idol expression and decreased hepatic LDL-receptor levels.
Ishibashi M; Masson D; Westerterp M; Wang N; Sayers S; Li R; Welch CL; Tall AR
J Lipid Res; 2010 Sep; 51(9):2655-63. PubMed ID: 20562239
[TBL] [Abstract][Full Text] [Related]
6. Targeted disruption of the idol gene alters cellular regulation of the low-density lipoprotein receptor by sterols and liver x receptor agonists.
Scotti E; Hong C; Yoshinaga Y; Tu Y; Hu Y; Zelcer N; Boyadjian R; de Jong PJ; Young SG; Fong LG; Tontonoz P
Mol Cell Biol; 2011 May; 31(9):1885-93. PubMed ID: 21343340
[TBL] [Abstract][Full Text] [Related]
7. Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation.
Tavori H; Fan D; Blakemore JL; Yancey PG; Ding L; Linton MF; Fazio S
Circulation; 2013 Jun; 127(24):2403-13. PubMed ID: 23690465
[TBL] [Abstract][Full Text] [Related]
8. Peroxisome Proliferator-activated receptor γ activation by ligands and dephosphorylation induces proprotein convertase subtilisin kexin type 9 and low density lipoprotein receptor expression.
Duan Y; Chen Y; Hu W; Li X; Yang X; Zhou X; Yin Z; Kong D; Yao Z; Hajjar DP; Liu L; Liu Q; Han J
J Biol Chem; 2012 Jul; 287(28):23667-77. PubMed ID: 22593575
[TBL] [Abstract][Full Text] [Related]
9. Activation of Adiponectin Receptor Regulates Proprotein Convertase Subtilisin/Kexin Type 9 Expression and Inhibits Lesions in ApoE-Deficient Mice.
Sun L; Yang X; Li Q; Zeng P; Liu Y; Liu L; Chen Y; Yu M; Ma C; Li X; Li Y; Zhang R; Zhu Y; Miao QR; Han J; Duan Y
Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):1290-1300. PubMed ID: 28546220
[TBL] [Abstract][Full Text] [Related]
10. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
11. Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor.
Sun H; Samarghandi A; Zhang N; Yao Z; Xiong M; Teng BB
Arterioscler Thromb Vasc Biol; 2012 Jul; 32(7):1585-95. PubMed ID: 22580899
[TBL] [Abstract][Full Text] [Related]
12. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP
Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370
[TBL] [Abstract][Full Text] [Related]
13. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
Zaid A; Roubtsova A; Essalmani R; Marcinkiewicz J; Chamberland A; Hamelin J; Tremblay M; Jacques H; Jin W; Davignon J; Seidah NG; Prat A
Hepatology; 2008 Aug; 48(2):646-54. PubMed ID: 18666258
[TBL] [Abstract][Full Text] [Related]
14. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype.
Maxwell KN; Breslow JL
Proc Natl Acad Sci U S A; 2004 May; 101(18):7100-5. PubMed ID: 15118091
[TBL] [Abstract][Full Text] [Related]
15. Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9.
van der Tuin SJ; Kühnast S; Berbée JF; Verschuren L; Pieterman EJ; Havekes LM; van der Hoorn JW; Rensen PC; Jukema JW; Princen HM; Willems van Dijk K; Wang Y
J Lipid Res; 2015 Nov; 56(11):2085-93. PubMed ID: 26342106
[TBL] [Abstract][Full Text] [Related]
16. Alginate oligosaccharide enhances LDL uptake via regulation of LDLR and PCSK9 expression.
Yang JH; Bang MA; Jang CH; Jo GH; Jung SK; Ki SH
J Nutr Biochem; 2015 Nov; 26(11):1393-400. PubMed ID: 26320675
[TBL] [Abstract][Full Text] [Related]
17. Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo.
Schmidt RJ; Beyer TP; Bensch WR; Qian YW; Lin A; Kowala M; Alborn WE; Konrad RJ; Cao G
Biochem Biophys Res Commun; 2008 Jun; 370(4):634-40. PubMed ID: 18406350
[TBL] [Abstract][Full Text] [Related]
18. Ascorbic acid enhances low-density lipoprotein receptor expression by suppressing proprotein convertase subtilisin/kexin 9 expression.
Wang D; Yang X; Chen Y; Gong K; Yu M; Gao Y; Wu X; Hu H; Liao C; Han J; Duan Y
J Biol Chem; 2020 Nov; 295(47):15870-15882. PubMed ID: 32913121
[TBL] [Abstract][Full Text] [Related]
19. MMP-2 inhibits PCSK9-induced degradation of the LDL receptor in Hepa1-c1c7 cells.
Wang X; Berry E; Hernandez-Anzaldo S; Sun D; Adijiang A; Li L; Zhang D; Fernandez-Patron C
FEBS Lett; 2015 Feb; 589(4):490-6. PubMed ID: 25613181
[TBL] [Abstract][Full Text] [Related]
20. Reduction of circulating PCSK9 and LDL-C levels by liver-specific knockdown of HNF1α in normolipidemic mice.
Shende VR; Wu M; Singh AB; Dong B; Kan CF; Liu J
J Lipid Res; 2015 Apr; 56(4):801-9. PubMed ID: 25652089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
